<unk> , previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1.  It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV.
Vicriviroc
Niraparib
Adefovir
Fomivirsen
Tecovirimat
Diprenorfin
Trifenfos
Temoporfin